258 related articles for article (PubMed ID: 37189251)
1. Emerging strategies for cancer therapy by ATR inhibitors.
Yano K; Shiotani B
Cancer Sci; 2023 Jul; 114(7):2709-2721. PubMed ID: 37189251
[TBL] [Abstract][Full Text] [Related]
2. Dormant origin signaling during unperturbed replication.
Moiseeva TN; Bakkenist CJ
DNA Repair (Amst); 2019 Sep; 81():102655. PubMed ID: 31311769
[TBL] [Abstract][Full Text] [Related]
3. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
[TBL] [Abstract][Full Text] [Related]
4. The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork.
Saldanha J; Rageul J; Patel JA; Kim H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445667
[TBL] [Abstract][Full Text] [Related]
5. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
6. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
7. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
9. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
10. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
Ngoi NYL; Peng G; Yap TA
Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
Mutat Res; 2023; 827():111834. PubMed ID: 37531716
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms used by cancer cells to tolerate drug-induced replication stress.
Segeren HA; Westendorp B
Cancer Lett; 2022 Sep; 544():215804. PubMed ID: 35750276
[TBL] [Abstract][Full Text] [Related]
14. An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.
Moiseeva TN; Yin Y; Calderon MJ; Qian C; Schamus-Haynes S; Sugitani N; Osmanbeyoglu HU; Rothenberg E; Watkins SC; Bakkenist CJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13374-13383. PubMed ID: 31209037
[TBL] [Abstract][Full Text] [Related]
15. Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
[TBL] [Abstract][Full Text] [Related]
16. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
17. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1.
Moiseeva T; Hood B; Schamus S; O'Connor MJ; Conrads TP; Bakkenist CJ
Nat Commun; 2017 Nov; 8(1):1392. PubMed ID: 29123096
[TBL] [Abstract][Full Text] [Related]
18. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
19. Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors.
Schleicher EM; Dhoonmoon A; Jackson LM; Clements KE; Stump CL; Nicolae CM; Moldovan GL
PLoS Genet; 2020 Nov; 16(11):e1009176. PubMed ID: 33137164
[TBL] [Abstract][Full Text] [Related]
20. An extending ATR-CHK1 circuitry: the replication stress response and beyond.
Simoneau A; Zou L
Curr Opin Genet Dev; 2021 Dec; 71():92-98. PubMed ID: 34329853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
